R. Besuyen

1.4k total citations
41 papers, 692 citations indexed

About

R. Besuyen is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, R. Besuyen has authored 41 papers receiving a total of 692 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Rheumatology, 22 papers in Genetics and 13 papers in Hematology. Recurrent topics in R. Besuyen's work include Rheumatoid Arthritis Research and Therapies (22 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Spondyloarthritis Studies and Treatments (11 papers). R. Besuyen is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Chronic Lymphocytic Leukemia Research (20 papers) and Spondyloarthritis Studies and Treatments (11 papers). R. Besuyen collaborates with scholars based in United States, Belgium and United Kingdom. R. Besuyen's co-authors include Chantal Tasset, Luc Meuleners, Joy M. Greer, Walid Abi‐Saab, Neelufar Mozaffarian, Thijs Hendrikx, Robert Landewé, Ke Liu, Xenofon Baraliakos and Walter P. Maksymowych and has published in prestigious journals such as The Lancet, Gastroenterology and The Journal of Urology.

In The Last Decade

R. Besuyen

41 papers receiving 685 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Besuyen United States	13	499	271	245	141	95	41	692
Myrna Cardiel United States	3	539 1.1×	162 0.6×	304 1.2×	157 1.1×	157 1.7×	5	711
Sarah Witt United States	5	422 0.8×	96 0.4×	213 0.9×	135 1.0×	130 1.4×	6	560
M. McIlraith United States	7	225 0.5×	362 1.3×	130 0.5×	63 0.4×	49 0.5×	18	670
J. Cush United States	8	251 0.5×	182 0.7×	103 0.4×	47 0.3×	47 0.5×	16	516
Caterina Micò Italy	11	84 0.2×	83 0.3×	303 1.2×	128 0.9×	292 3.1×	19	615
George Vratsanos United States	9	519 1.0×	296 1.1×	186 0.8×	34 0.2×	123 1.3×	13	738
Sandra Garcês Portugal	8	230 0.5×	302 1.1×	77 0.3×	41 0.3×	89 0.9×	16	567
S Songcharoen United States	6	421 0.8×	141 0.5×	184 0.8×	104 0.7×	123 1.3×	7	654
A. Covucci United States	4	546 1.1×	164 0.6×	258 1.1×	26 0.2×	171 1.8×	6	654
Mario Ojeda‐Uribe France	11	60 0.1×	159 0.6×	164 0.7×	99 0.7×	111 1.2×	34	486

Countries citing papers authored by R. Besuyen

Since Specialization

Citations

This map shows the geographic impact of R. Besuyen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Besuyen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Besuyen more than expected).

Fields of papers citing papers by R. Besuyen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Besuyen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Besuyen. The network helps show where R. Besuyen may publish in the future.

Co-authorship network of co-authors of R. Besuyen

This figure shows the co-authorship network connecting the top 25 collaborators of R. Besuyen. A scholar is included among the top collaborators of R. Besuyen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Besuyen. R. Besuyen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Westhovens, René, Kevin Winthrop, Arthur Kavanaugh, et al.. (2025). Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study. RMD Open. 11(1). e004857–e004857. 2 indexed citations

Harrison, Stephen A., Naim Alkhouri, Grisell Ortiz‐Lasanta, et al.. (2025). A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH. Journal of Hepatology. 83(2). 293–303. 4 indexed citations

Watkins, Timothy R., Quan Dong Nguyen, David K. Scales, et al.. (2024). Filgotinib in Active Noninfectious Uveitis. JAMA Ophthalmology. 142(9). 789–789. 7 indexed citations

Reinisch, Walter, Wayne J.G. Hellstrom, Radboud J. E. M. Dolhain, et al.. (2023). Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies. Annals of the Rheumatic Diseases. 82(8). 1049–1058. 20 indexed citations

Hibi∥, Toshifumi, Satoshi Motoya, Tadakazu Hisamatsu, et al.. (2022). Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intestinal Research. 21(1). 110–125. 13 indexed citations

Combe, Bernard, et al.. (2022). Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatology and Therapy. 10(1). 35–51. 1 indexed citations

Maksymowych, Walter P., Mikkel Østergaard, Robert Landewé, et al.. (2021). Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Lara D. Veeken. 61(6). 2388–2397. 16 indexed citations

Coates, Laura C., Philip Helliwell, Filip Van den Bosch, et al.. (2021). POS1049 EFFECT OF FILGOTINIB ON PASDAS: DRIVERS OF LOW AND VERY LOW ACTIVITY UP TO WEEK 100. Annals of the Rheumatic Diseases. 80. 801–802. 1 indexed citations

Kavanaugh, Arthur, René Westhovens, Kevin Winthrop, et al.. (2021). Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. The Journal of Rheumatology. 48(8). 1230–1238. 37 indexed citations

10.

Winthrop, Kevin, Yoshiya Tanaka, Tsutomu Takeuchi, et al.. (2021). Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years. Annals of the Rheumatic Diseases. 81(2). 184–192. 62 indexed citations

11.

Baraliakos, Xenofon, Mikkel Østergaard, R. B. M. Landewé, et al.. (2021). OP0141 EFFECTS OF FILGOTINIB ON SPINAL LESIONS IN ANKYLOSING SPONDYLITIS: MAGNETIC RESONANCE IMAGING DATA FROM THE TORTUGA TRIAL. Annals of the Rheumatic Diseases. 80. 83–84. 1 indexed citations

12.

Gladman, Dafna D., Andrew Hertz, Madhukar H. Trivedi, et al.. (2020). OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS. Annals of the Rheumatic Diseases. 79. 140–140. 1 indexed citations

13.

Husni, M. Elaine, Dafna D. Gladman, Philip Helliwell, et al.. (2020). FRI0344 THE LONG-TERM EFFECT OF TREATING PSORIATIC ARTHRITIS WITH THE JANUS KINASE 1-SELECTIVE INHIBITOR FILGOTINIB ON LIPID PROFILES: AN ANALYSIS OF THE EQUATOR AND EQUATOR2 TRIALS. Annals of the Rheumatic Diseases. 79. 766–766. 2 indexed citations

14.

Besuyen, R., Mark C. Genovese, Kurt de Vlam, et al.. (2020). P372 Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: Phase 3 study results in patients with active rheumatoid arthritis and prior inadequate response/intolerance to biological DMARDs. Journal of Crohn s and Colitis. 14(Supplement_1). S350–S352. 1 indexed citations

15.

Helliwell, Philip, Filip Van den Bosch, Laura C. Coates, et al.. (2020). FRI0343 EFFICACY AND SAFETY OF FILGOTINIB, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: SUBGROUP ANALYSES FROM A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL (EQUATOR). Annals of the Rheumatic Diseases. 79. 765–766. 3 indexed citations

16.

Genovese, Mark C., Kevin Winthrop, Yoshiya Tanaka, et al.. (2020). THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS. Annals of the Rheumatic Diseases. 79. 324–325. 11 indexed citations

17.

Orbai, Ana‐Maria, Alexis Ogdie, Laure Gossec, et al.. (2019). Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). Lara D. Veeken. 59(7). 1495–1504. 22 indexed citations

18.

D’Hooghe, Thomas, Takao Fukaya, Yutaka Osuga, et al.. (2019). Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study. Human Reproduction. 34(5). 813–823. 12 indexed citations

19.

Binkley, Neil, R. Besuyen, Thomas Fuerst, Laurence Skillern, & Didier Hans. (2017). Is drug-induced bone loss acceptable in premenopausal women? A practical fracture risk modeling exercise. Osteoporosis International. 28(12). 3501–3513. 7 indexed citations

20.

Newgreen, Donald, et al.. (2016). Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial. European Urology. 71(3). 483–490. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact